Streetwise Biotech / Pharmaceuticals Articles



John McCamant

Biotech Round-Up: M&As, Financings and Immuno-Oncology
Source: John McCamant for Streetwise Reports  (4/18/18)
John McCamant, editor of Medical Technology Stock Letter, reviews biotech M&A and financings, and discusses one company that is expanding its immuno-oncology pipeline. More >


Major Cannabis Player Sees Florida Sales Surge Over 250% and Will Acquire 75% Ownership in Massachusetts Deal
Source: Streetwise Reports  (4/17/18)
A medicinal cannabis company has seen its Florida sales increase 253%, and the company just gained 75% control over a Massachusetts-based dispensary operation, expanding its influence in the medicinal marijuana industry. More >


Biotech Gets Cashed Up Ahead of Pivotal Phase 3 Readouts
Source: Streetwise Reports  (4/17/18)
Ram Selvaraju, an analyst with H.C. Wainwright & Co., discussed the capital raise and upcoming clinical trial data.


More >


Biotech with Deep Pipeline, 'Abundant' Upcoming Catalysts Named Top Pick
Source: Streetwise Reports  (4/11/18)
Douglas Loe, an analyst with Echelon Wealth Partners, made the case for why this biopharmaceutical company merits this status.
More >


Biotech Announces Positive Topline Data in Tourette Syndrome
Source: Streetwise Reports  (4/11/18)
Francois Brisebois, a Laidlaw & Co. analyst, reviewed the recently released study results and upcoming catalysts. More >


RNAi Therapeutics Developer Reports Positive Amyloidosis Data
Source: Streetwise Reports  (4/4/18)
Michael King, an analyst with JMP Securities, reported the new results that this biotech presented in March. More >


CMS Unexpectedly Issues Product Billing Code to Biotech
Source: Streetwise Reports  (4/4/18)
Francois Brisebois, an analyst with Laidlaw & Co., shared and weighed in on the latest news regarding this biopharmaceutical firm.
More >


John McCamant

Biotech Delivers 'Excellent' Phase 2 Data
Source: John McCamant for Streetwise Reports  (4/3/18)
John McCamant, editor of Medical Technology Stock Letter, discusses a biotech with data that he views as positive from a Phase 2 LDL cholesterol lowering trial. More >


Medical Device Firm Posts 'Strong Performance' Globally in Q4/17
Source: Streetwise Reports   (3/28/18)
The company performed strongly in the U.S. and the Asia Pacific region. More >


Regrouped Biotech's Stock Price Could See Fifteenfold Increase
Source: Streetwise Reports  (3/28/18)
A recent conference call provided clinical and financial updates. More >


Andrea Bartzen

Convergence Will Drive the Ultimate Disruption of Life Sciences
Source: Andrea Bartzen for Streetwise Reports  (3/28/18)
Andrea Bartzen, a strategic commercial and communication consultant, describes the disruptive technologies positioned to radically alter the business of life sciences as discussed at a recent BIO CEO Summit Investor Night.
More >


Biotech Advances Treatments for Liver Disease, Pain, Mental Illness
Source: Streetwise Reports  (3/22/18)
With a pipeline expected to generate news flow throughout 2018, this company anticipates a productive 2018.
More >


Two Biotechs Earn Analyst's Top Pick Ranking
Source: Streetwise Reports  (3/19/18)
Echelon Wealth Partners analyst Doug Loe sees blue sky potential for one company's newly approved HIV compound, while the vaccine platform of a second company earned it Top Pick status as well.
More >


Price Target on Biotech Is a 700% Potential Increase
Source: Streetwise Reports  (3/19/18)
Ram Selvaraju, an analyst with H.C. Wainwright & Co., explained Phase 2 data recently released by this company, which documented improvements in patients with inflammatory bowel disease. More >


Biotech's Encouraging Phase 2 Gut Microbiome Data 'Bodes Well' for Phase 3
Source: Streetwise Reports  (3/14/18)
H.C. Wainwright & Co. analyst Ram Selvaraju reported the latest study findings involving this biotherapeutic firm's lead asset. More >


Coverage Initiated on Biotech; Analyst Says, 'Time to Buy'
Source: Streetwise Reports  (3/14/18)
Sarah Weber, an analyst with Piper Jaffray & Co., made the case for investing in this biotherapeutic development firm. More >


Coverage Initiated on Biotech with Interference RNA Platform; Target Price Shows 600% Upside
Source: Streetwise Reports  (3/7/18)
John Vandermosten, an analyst with Zacks Small-Cap Research, analyzed this therapeutics development firm as an investment. More >


Biotech Launches Trial Dosing Against Backdrop of Strong Balance Sheet
Source: Streetwise Reports  (3/7/18)
Four analysts provided updates regarding the status of this firm's financials and one of its clinical programs. More >


Coverage Launched on Biotech That Could 'Disrupt the Skin Regeneration Market'
Source: Streetwise Reports  (2/23/18)
Elemer Piros, a Cantor Fitzgerald analyst, explained this company's lead product, including how it works, its success to date and its market potential.
More >


Steve Palmer

Fund Manager Names Three Small-Caps with Strong Growth Profiles
Source: Streetwise Reports  (2/22/18)
The annual AlphaNorth Capital Conference features small-cap non-resource companies with high growth prospects. AlphaNorth's founder and chief investment officer, Steve Palmer, profiles several companies that he believes have bright prospects.
More >


Analyst's $70 Target Price on Regenerative Medicine Biotech More than a Triple
Source: Streetwise Reports  (2/20/18)
One analyst believes an innovative biotech company that has developed groundbreaking technology to change the way doctors perform body tissue engineering, like skin grafting on burn victims, has the potential to "revolutionize the field of regenerative medicine." More >


Biotech with Tenbagger Potential Signs Deal with Chinese Firm
Source: Streetwise Reports  (2/14/18)
Joseph Pantginis, an analyst with H. C. Wainwright & Co., detailed prospects for this biopharmaceutical corporation's new partnership with an Asian biotech and other near-term plans.
More >


Ron Struthers

The S-Curve Reveals It Is Early Days in the Marijuana Growth Cycle
Source: Ron Struthers for Streetwise Reports  (2/12/18)
Ron Struthers of Struthers Resource Stock Report discusses recent trends in cannabis investing and profiles a handful of cannabis companies. More >


Oncology Biotech with Precision Medicine Focus Added to Analyst's 2018 Top-Pick List
Source: Streetwise Reports  (2/7/18)
A small-cap biotech focused on developing customized treatments for cancer patients has earned inclusion on the NASDAQ Biotechnology Index, as well as caught the eye of analyst Michael King of JMP Securities. More >


Immuno-oncology Pure Play 'Ideally Positioned to Capture Value'
Source: Streetwise Reports  (2/7/18)
Maxim Group analyst Jason McCarthy explained why investors should focus on this emerging technology and one developer that is well-positioned to capture value in the space. More >


Showing Results: 26 to 50 of 758 Prev Next

Notable Quotes

"We are initiating coverage on PMN."
– John Vandermosten, Zacks Small-Cap Research

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts